

Senate
Study
Bill
3155
-
Introduced


SENATE
FILE
_____


BY
(PROPOSED
COMMITTEE


ON
COMMERCE
BILL
BY


CHAIRPERSON
DAWSON)


A
BILL
FOR


An
Act
relating
to
pharmaceutical
drug
manufacturers
and
1


prescription
drug
prices,
and
including
applicability
2


provisions.
3


BE
IT
ENACTED
BY
THE
GENERAL
ASSEMBLY
OF
THE
STATE
OF
IOWA:
4


TLSB
5828XC
(4)
88


ko/rn



S.F.
_____


Section
1.
NEW
SECTION
.
510D.1
Definitions.
1


As
used
in
this
chapter,
unless
the
context
otherwise
2


requires:
3


1.
“Commissioner”
means
the
commissioner
of
insurance.
4


2.
“Dispenser”
means
the
same
as
defined
in
21
U.S.C.
5


§360eee(3).
6


3.
“Established
name”
means
the
same
as
defined
in
21
C.F.R.
7


§299.4.
8


4.
“New
prescription
drug”
or
“new
drug”
means
a
9


prescription
drug
approved
by
the
United
States
food
and
drug
10


administration
for
which
a
wholesale
acquisition
cost
has
not
11


been
previously
established.
12


5.
“Newly
acquired
prescription
drug”
or
“newly
acquired
13


drug”
means
a
prescription
drug
approved
by
the
United
States
14


food
and
drug
administration
that
has
been
researched
and
15


developed
by
an
entity
other
than
the
pharmaceutical
drug
16


manufacturer
that
acquires
the
right
to
sell
the
prescription
17


drug.
18


6.
“Patient
assistance
program”
means
a
program
a
19


pharmaceutical
drug
manufacturer
offers
to
the
general
public
20


in
which
a
consumer
may
reduce
the
consumer’s
out-of-pocket
21


cost
for
a
prescriptions
drug
by
using
a
coupon,
discount
card,
22


pharmaceutical
drug
manufacturer
debit
card,
or
other
means
23


provided
by
the
pharmaceutical
drug
manufacturer.
24


7.
“Pharmaceutical
drug
manufacturer”
or
“manufacturer”
means
25


any
person
engaged
in
the
business
of
producing,
preparing,
26


converting,
processing,
packaging,
labeling,
or
distributing
27


a
prescription
drug
that
is
sold
to
any
person
in
this
state.
28


“Pharmaceutical
drug
manufacturer”
or
“manufacturer”
does
not
29


include
a
wholesaler
distributor
or
a
dispenser.
30


8.
“Prescription
drug”
means
the
same
as
defined
in
21
31


U.S.C.
§360eee(12).
32


9.
“Price”
means
the
wholesale
acquisition
cost
as
defined
33


in
42
U.S.C.
§1395w-3a(c)(6)(B).
34


10.
“Wholesale
acquisition
cost”
means
the
same
as
defined
35


-1-


LSB
5828XC
(4)
88


ko/rn
1/
8




S.F.
_____


in
42
U.S.C.
§1395w-3a(c)(6)(B).
1


11.
“Wholesale
distributor”
means
the
same
as
defined
in
21
2


U.S.C.
§360eee(29).
3


Sec.
2.
NEW
SECTION


.
510D.2
Pharmaceutical
drug
4


manufacturers
——
prescription
drugs
——
reporting
requirements.
5


1.
A
pharmaceutical
drug
manufacturer
shall
submit
the
6


information
pursuant
to
subsection
2
to
the
commissioner
for
7


each
prescription
drug
manufactured
by
the
manufacturer
to
8


which
all
of
the
following
apply:
9


a.
The
price
of
the
prescription
drug
is
one
hundred
dollars
10


or
more
for
a
thirty-day
supply,
or
for
a
course
of
treatment
11


lasting
less
than
thirty
days.
12


b.
The
price
of
the
prescription
drug
increases
an
amount
13


greater
than
the
percentage
increase
in
the
most
recent
14


consumer
price
index
published
in
the
federal
register
by
the
15


United
States
department
of
labor,
bureau
of
labor
statistics.
16


2.
Within
sixty
calendar
days
of
the
date
of
a
price
17


increase
pursuant
to
subsection
1,
paragraph
“b”
,
the
18


manufacturer
shall
submit,
in
the
form
and
manner
prescribed
by
19


the
commissioner,
all
of
the
following
information:
20


a.
The
established
name
and
the
brand
name
of
the
21


prescription
drug,
the
current
price
of
the
prescription
drug,
22


and
the
net
price
increase
of
the
prescription
drug
expressed
23


as
a
percentage.
24


b.
A
statement
detailing
all
factors
that
contributed
to
25


the
price
increase
of
the
prescription
drug
and
an
explanation
26


regarding
the
impact
each
factor
had
on
the
price
increase.
27


c.
The
brand
name
of
all
generic
versions
of
the
28


prescription
drug
currently
available
on
the
consumer
market.
29


d.
The
initial
price
of
the
prescription
drug
after
it
was
30


approved
by
the
United
States
food
and
drug
administration.
31


e.
If
applicable,
the
annual
net
price
increase,
expressed
32


as
a
percentage,
of
the
prescription
drug
for
each
of
the
five
33


immediately
preceding
calendar
years.
34


f.
For
the
immediately
preceding
twelve
consecutive
months,
35


-2-


LSB
5828XC
(4)
88


ko/rn
2/
8




S.F.
_____


the
average
price
of
the
prescription
drug
in
each
of
the
ten
1


countries
outside
of
the
United
States
with
the
highest
sales
2


of
the
prescription
drug.
3


g.
The
aggregate
direct
and
administrative
costs
incurred
by
4


the
manufacturer
related
to
any
of
the
following:
5


(1)
Manufacturing
the
prescription
drug.
6


(2)
Marketing
and
advertising
the
prescription
drug.
7


(3)
Researching
and
developing
the
prescription
drug.
8


(4)
Distributing
the
prescription
drug.
9


h.
The
net
revenue
generated
for
the
manufacturer
10


attributable
to
the
sale
of
the
prescription
drug
during
the
11


immediately
preceding
twelve
consecutive
months.
12


i.
The
net
profit
generated
for
the
manufacturer
13


attributable
to
the
prescription
drug
during
the
immediately
14


preceding
twelve
consecutive
months.
15


j.
The
aggregate
cost
to
the
manufacturer
of
any
patient
16


assistance
programs
associated
with
the
prescription
drug.
17


k.
If
applicable,
the
patent
expiration
date
for
the
18


prescription
drug.
19


l.
If
applicable,
the
exclusivity
expiration
date
for
the
20


prescription
drug.
21


m.
Whether
an
agreement
exists
between
the
manufacturer
22


and
any
another
entity
or
entities
requiring
the
other
23


entity
or
entities
to
delay
offering
a
generic
version
of
the
24


manufacturer’s
prescription
drug
on
the
open
market.
25


Sec.
3.
NEW
SECTION


.
510D.3
Pharmaceutical
drug
26


manufacturers
——
new
prescription
drugs
——
reporting
27


requirements.
28


1.
A
pharmaceutical
drug
manufacturer
shall
submit
the
29


information
pursuant
to
subsection
2
to
the
commissioner
for
30


each
prescription
drug
manufactured
by
the
manufacturer
to
31


which
any
of
the
following
apply:
32


a.
The
prescription
drug
is
a
new
drug
that
has
a
price
33


greater
than
five
hundred
dollars
for
a
thirty-day
supply.
34


b.
The
prescription
drug
is
a
generic
new
drug
that
has
a
35


-3-


LSB
5828XC
(4)
88


ko/rn
3/
8




S.F.
_____


price
greater
than
two
hundred
dollars
for
a
thirty-day
supply.
1


2.
Within
sixty
calendar
days
of
the
first
date
the
2


manufacturer
offers
the
new
drug
in
this
state,
the
3


manufacturer
shall
submit,
in
the
form
and
manner
prescribed
by
4


the
commissioner,
all
of
the
following
information:
5


a.
The
price
of
the
new
drug.
6


b.
The
established
name
and
the
brand
name
of
the
new
drug.
7


c.
The
brand
name
of
the
generic
version,
if
applicable.
8


d.
Whether
the
new
drug
received
a
breakthrough
9


therapy
designation
from
the
United
States
food
and
drug
10


administration.
11


e.
Whether
the
new
drug
received
a
priority
review
12


designation
from
the
United
States
food
and
drug
13


administration.
14


f.
The
aggregate
direct
and
administrative
costs
incurred
by
15


the
manufacturer
for
all
of
the
following:
16


(1)
Manufacturing
the
new
drug.
17


(2)
Marketing
and
advertising
the
new
drug.
18


(3)
Researching
and
developing
the
new
drug.
19


(4)
Distributing
the
new
drug.
20


g.
If
applicable,
the
patent
expiration
date
for
the
new
21


drug.
22


h.
If
applicable,
the
exclusivity
expiration
date
for
the
23


new
drug.
24


Sec.
4.
NEW
SECTION


.
510D.4
Pharmaceutical
drug
25


manufacturers
——
newly
acquired
prescription
drugs
——
reporting
26


requirements.
27


1.
For
each
newly
acquired
prescription
drug
for
which
28


the
net
price
increases
by
more
than
one
hundred
dollars
on
29


or
after
the
date
of
a
manufacturer’s
acquisition
of
the
30


new
drug,
the
acquiring
manufacturer
shall
submit
to
the
31


commissioner,
within
sixty
calendar
days
of
the
date
the
32


acquiring
manufacturer
offers
the
newly
acquired
drug
in
this
33


state,
all
of
the
following
information:
34


a.
The
date
on
which
the
newly
acquired
drug
was
acquired.
35


-4-


LSB
5828XC
(4)
88


ko/rn
4/
8




S.F.
_____


b.
The
price
of
the
newly
acquired
drug
on
the
date
of
1


acquisition.
2


c.
If
applicable,
the
average
price
of
the
newly
acquired
3


drug
during
each
of
the
twelve
consecutive
months
immediately
4


preceding
the
date
of
acquisition.
5


d.
If
applicable,
the
average
net
price
of
the
newly
6


acquired
drug
during
each
of
the
five
consecutive
calendar
7


years
immediately
preceding
the
date
of
acquisition.
8


e.
The
identity
of
the
entity
from
which
the
acquiring
9


manufacturer
acquired
the
newly
acquired
drug.
10


f.
The
date
that
the
newly
acquired
drug
was
originally
11


offered
on
the
consumer
market
and
the
price
of
the
newly
12


acquired
drug
on
that
date.
13


g.
Whether
an
agreement
exists
between
the
manufacturer
14


and
any
another
entity
or
entities
requiring
the
other
15


entity
or
entities
to
delay
offering
a
generic
version
of
the
16


manufacturer’s
newly
acquired
drug
on
the
consumer
market.
17


h.
If
applicable,
the
new
drug’s
patent
expiration
date.
18


i.
If
applicable,
the
new
drug’s
exclusivity
expiration
19


date.
20


Sec.
5.
NEW
SECTION


.
510D.5
Prescription
drug
pricing
——
21


public
availability.
22


1.
Information
provided
by
a
pharmaceutical
drug
23


manufacturer
to
the
commissioner
pursuant
to
sections
510D.2,
24


510D.3,
and
510D.4
that
may
reveal
any
of
the
following
25


as
related
to
a
specific
prescription
drug
or
class
of
26


prescription
drugs
shall
be
considered
a
confidential
record,
27


and
be
recognized
and
protected
as
a
trade
secret
pursuant
to
28


section
22.7,
subsection
3:
29


a.
The
amount
the
manufacturer
charges
a
specific
health
30


carrier,
specific
pharmacy
benefit
manager,
or
a
specific
31


dispenser.
32


b.
The
dollar
value
of
the
rebates
the
manufacturer
provides
33


a
specific
health
carrier,
specific
pharmacy
benefit
manager,
34


or
a
specific
dispenser.
35


-5-


LSB
5828XC
(4)
88


ko/rn
5/
8




S.F.
_____


c.
The
identity
of
a
specific
health
carrier,
specific
1


pharmacy
benefit
manager,
or
a
specific
dispenser.
2


2.
Within
sixty
calendar
days
of
receipt,
the
commissioner
3


shall
publish
the
nonconfidential
information
provided
pursuant
4


to
sections
510D.2,
510D.3,
and
510D.4
on
a
publicly
accessible
5


internet
site.
6


Sec.
6.
NEW
SECTION


.
510D.6
Rules.
7


The
commissioner
may
adopt
rules
pursuant
to
chapter
17A
as
8


necessary
to
administer
this
chapter.
9


Sec.
7.
NEW
SECTION


.
510D.7
Enforcement.
10


The
commissioner
may
take
any
action
within
the
11


commissioner’s
authority
to
enforce
compliance
with
this
12


chapter.
13


Sec.
8.
APPLICABILITY.
14


1.
The
section
of
this
Act
requiring
a
manufacturer
to
15


submit
a
report
regarding
existing
prescription
drugs
to
16


the
commissioner
applies
to
a
manufacturer
that
sells
a
17


prescription
drug
to
any
person
in
this
state
on
or
after
July
18


1,
2020.
19


2.
The
section
of
this
Act
requiring
a
manufacturer
to
20


submit
a
report
regarding
new
prescription
drugs
to
the
21


commissioner
applies
to
a
manufacturer
that
sells
a
new
22


prescription
drug
to
any
person
in
this
state
on
or
after
March
23


15,
2021.
24


3.
The
section
of
this
Act
requiring
a
manufacturer
to
25


submit
a
report
regarding
newly
acquired
prescription
drugs
to
26


the
commissioner
applies
to
a
manufacturer
that
sells
a
newly
27


acquired
prescription
drug
to
any
person
in
this
state
on
or
28


after
July
1,
2021.
29


EXPLANATION
30


The
inclusion
of
this
explanation
does
not
constitute
agreement
with
31


the
explanation’s
substance
by
the
members
of
the
general
assembly.
32


This
bill
relates
to
pharmaceutical
drug
manufacturers
and
33


prescription
drug
prices.
34


If
the
price
of
a
prescription
drug
is
$100
or
more
for
a
35


-6-


LSB
5828XC
(4)
88


ko/rn
6/
8





S.F.
_____


30-day
supply
or
for
a
course
of
treatment
lasting
less
than
1


30
days;
or
the
price
of
a
prescription
drug
increases
by
an
2


amount
greater
than
the
percentage
increase
of
the
most
recent
3


consumer
price
index
published
by
the
United
States
department
4


of
labor,
bureau
of
labor
statistics,
the
bill
requires
a
5


pharmaceutical
drug
manufacturer
(manufacturer)
to
submit
a
6


report
to
the
commissioner
of
insurance
(commissioner)
that
7


includes
information
as
outlined
in
the
bill.
The
report
8


must
be
submitted
within
60
calendar
days
of
the
date
of
the
9


applicable
price
increase.
“Price”
is
defined
in
the
bill
10


as
the
wholesale
acquisition
cost
of
the
drug.
“Wholesale
11


acquisition
cost”
is
the
manufacturer’s
list
price
for
a
drug
12


to
wholesalers
or
direct
purchasers
in
the
United
States,
not
13


including
prompt
pay
or
other
discounts,
rebates
or
reductions
14


in
price,
for
the
most
recent
month
for
which
the
information
15


is
available,
as
reported
in
wholesale
price
guides
or
other
16


publications
of
drug
pricing
data.
“Pharmaceutical
drug
17


manufacturer”
or
“manufacturer”
is
defined
in
the
bill
as
18


any
person
engaged
in
the
business
of
producing,
preparing,
19


converting,
processing,
packaging,
labeling,
or
distributing
20


a
prescription
drug
that
is
sold
to
any
person
in
this
state.
21


The
definition
does
not
include
a
wholesale
distributor
or
a
22


dispenser,
both
of
which
are
also
defined
in
the
bill.
23


If
a
manufacturer’s
new
drug
has
a
price
greater
than
$500
24


for
a
30-day
supply,
or
a
generic
new
drug
that
has
a
price
25


greater
than
$200
for
a
30-day
supply,
within
60
calendar
days
26


of
the
first
date
the
manufacturer
makes
the
new
drug
available
27


in
this
state,
the
manufacturer
must
submit
a
report
to
the
28


commissioner
that
contains
the
information
outlined
in
the
29


bill.
The
bill
defines
“new
prescription
drug”
or
“new
drug”
30


as
a
prescription
drug
approved
by
the
United
States
food
and
31


drug
administration
for
which
a
wholesale
acquisition
cost
has
32


not
been
previously
established.
33


For
each
newly
acquired
prescription
drug
for
which
the
34


net
price
increases
by
more
than
$100
on
or
after
the
date
of
35


-7-


LSB
5828XC
(4)
88


ko/rn
7/
8



S.F.
_____


a
manufacturer’s
acquisition
of
the
new
drug,
the
acquiring
1


manufacturer
must
submit
a
report
to
the
commissioner,
within
2


60
calendar
days
of
the
date
the
acquiring
manufacturer
3


offers
the
newly
acquired
drug
in
this
state,
that
contains
4


information
as
detailed
in
the
bill.
“Newly
acquired
5


prescription
drug”
or
“newly
acquired
drug”
is
defined
in
the
6


bill
as
a
prescription
drug
approved
by
the
United
States
food
7


and
drug
administration
that
has
been
researched
and
developed
8


by
an
entity
other
than
the
pharmaceutical
drug
manufacturer
9


that
acquires
the
right
to
sell
the
prescription
drug.
10


Within
60
calendar
days
of
receipt,
the
bill
requires
the
11


commissioner
to
publish
the
nonconfidential
information,
as
12


described
in
the
bill,
from
the
required
reports
filed
by
13


manufacturers
on
a
publicly
accessible
internet
site.
14


The
commissioner
may
adopt
rules
as
necessary
to
administer
15


the
provisions
contained
in
the
bill.
The
commissioner
may
16


also
take
any
action
within
the
commissioner’s
authority
to
17


enforce
compliance
with
the
provisions
contained
in
the
bill.
18


The
section
of
the
bill
requiring
a
manufacturer
to
19


submit
a
report
regarding
existing
prescription
drugs
to
20


the
commissioner
applies
to
a
manufacturer
that
sells
a
21


prescription
drug
to
any
person
in
this
state
on
or
after
July
22


1,
2020.
The
section
of
the
bill
requiring
a
manufacturer
23


to
submit
a
report
regarding
new
prescription
drugs
to
the
24


commissioner
applies
to
a
manufacturer
that
sells
a
new
25


prescription
drug
to
any
person
in
this
state
on
or
after
March
26


15,
2021.
The
section
of
the
bill
requiring
a
manufacturer
to
27


submit
a
report
regarding
newly
acquired
prescription
drugs
to
28


the
commissioner
applies
to
a
manufacturer
that
sells
a
newly
29


acquired
prescription
drug
to
any
person
in
this
state
on
or
30


after
July
1,
2021.
31


-8-


LSB
5828XC
(4)
88


ko/rn
8/
8

